Metabolism of warfarin during methandrostenolone treatment. 1965

K Pyörälä, and G Myllylä, and M Kekki

UI MeSH Term Description Entries
D008696 Methandrostenolone A synthetic steroid with anabolic properties that are more pronounced than its androgenic effects. It has little progestational activity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1188) Dehydromethyltestosterone,Metandienone,Methandienone,Dianabol,Metanabol,Nerobol
D011516 Prothrombin A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia. Coagulation Factor II,Factor II,Blood Coagulation Factor II,Differentiation Reversal Factor,Factor II, Coagulation,Factor, Differentiation Reversal,II, Coagulation Factor
D001769 Blood The body fluid that circulates in the vascular system (BLOOD VESSELS). Whole blood includes PLASMA and BLOOD CELLS.
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005167 Factor VII Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor VIIa in the extrinsic pathway of blood coagulation. The activated form then catalyzes the activation of factor X to factor Xa. Coagulation Factor VII,Proconvertin,Stable Factor,Blood Coagulation Factor VII,Factor 7,Factor Seven,Factor VII, Coagulation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014859 Warfarin An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide. 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one,Aldocumar,Apo-Warfarin,Coumadin,Coumadine,Gen-Warfarin,Marevan,Tedicumar,Warfant,Warfarin Potassium,Warfarin Sodium,Potassium, Warfarin,Sodium, Warfarin
D066298 In Vitro Techniques Methods to study reactions or processes taking place in an artificial environment outside the living organism. In Vitro Test,In Vitro Testing,In Vitro Tests,In Vitro as Topic,In Vitro,In Vitro Technique,In Vitro Testings,Technique, In Vitro,Techniques, In Vitro,Test, In Vitro,Testing, In Vitro,Testings, In Vitro,Tests, In Vitro,Vitro Testing, In

Related Publications

K Pyörälä, and G Myllylä, and M Kekki
December 1960, Folia endocrinologica; mensile di incretologia e incretoterapia,
K Pyörälä, and G Myllylä, and M Kekki
January 1984, European journal of drug metabolism and pharmacokinetics,
K Pyörälä, and G Myllylä, and M Kekki
January 1965, Strahlentherapie,
K Pyörälä, and G Myllylä, and M Kekki
November 1967, The Journal of the Medical Society of New Jersey,
K Pyörälä, and G Myllylä, and M Kekki
May 1973, British journal of haematology,
K Pyörälä, and G Myllylä, and M Kekki
April 1964, La Riforma medica,
K Pyörälä, and G Myllylä, and M Kekki
January 1963, Scandinavian journal of clinical and laboratory investigation,
K Pyörälä, and G Myllylä, and M Kekki
January 1974, Scandinavian journal of haematology,
K Pyörälä, and G Myllylä, and M Kekki
March 2006, Vnitrni lekarstvi,
Copied contents to your clipboard!